BCMA CAR-T cell therapy / Chongqing Precision Biotech - LARVOL DELTA

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2024 ➔ Jul 2027 | Trial primary completion date: Dec 2023 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma

A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2024 ➔ Jul 2027 | Trial primary completion date: Dec 2023 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma • IL6

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Jan 2023 ➔ Dec 2023

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma • IL6

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2; N=80; Recruiting; Sponsor: Chongqing Precision Biotech Co., Ltd; Active, not recruiting ➔ Recruiting

CAR T-Cell Therapy • Clinical • Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma • IL6

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2; N=80; Active, not recruiting; Sponsor: Chongqing Precision Biotech Co., Ltd

CAR T-Cell Therapy • Clinical • New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma